
Sign up to save your podcasts
Or


๐ถโโ๏ธ The STRIDE trial tested semaglutide in patients with PAD and type 2 diabetes.
๐ Weekly injections for 52 weeks improved walking distance, pain-free mobility, and quality of life.
๐ Results showed significant gains vs placebo, with low adverse events.
๐ Semaglutide may offer a new stride forward in treating functional limitations in PAD.
By Dr RR Baliga, MD, MBA5
66 ratings
๐ถโโ๏ธ The STRIDE trial tested semaglutide in patients with PAD and type 2 diabetes.
๐ Weekly injections for 52 weeks improved walking distance, pain-free mobility, and quality of life.
๐ Results showed significant gains vs placebo, with low adverse events.
๐ Semaglutide may offer a new stride forward in treating functional limitations in PAD.

894 Listeners

3,376 Listeners

21,452 Listeners